{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T08:13:24Z","timestamp":1791015204764,"version":"4.1.0"},"reference-count":42,"publisher":"National Academy of Sciences","issue":"29","content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2008,7,22]]},"abstract":"<jats:p>Plant-made vaccines have been the subject of intense interest because they can be produced economically in large scale without the use of animal-derived components. Plant-made therapeutic vaccines against challenging chronic diseases, such as cancer, have received little research attention, and no previous human clinical trials have been conducted in this vaccine category. We document the feasibility of using a plant viral expression system to produce personalized (patient-specific) recombinant idiotype vaccines against follicular B cell lymphoma and the results of administering these vaccines to lymphoma patients in a phase I safety and immunogenicity clinical trial. The system allowed rapid production and recovery of idiotypic single-chain antibodies (scFv) derived from each patient's tumor and immunization of patients with their own individual therapeutic antigen. Both low and high doses of vaccines, administered alone or co-administered with the adjuvant GM-CSF, were well tolerated with no serious adverse events. A majority (&gt;70%) of the patients developed cellular or humoral immune responses, and 47% of the patients developed antigen-specific responses. Because 15 of 16 vaccines were glycosylated in plants, this study also shows that variation in patterns of antigen glycosylation do not impair the immunogenicity or affect the safety of the vaccines. Collectively, these findings support the conclusion that plant-produced idiotype vaccines are feasible to produce, safe to administer, and a viable option for idiotype-specific immune therapy in follicular lymphoma patients.<\/jats:p>","DOI":"10.1073\/pnas.0803636105","type":"journal-article","created":{"date-parts":[[2008,7,21]],"date-time":"2008-07-21T20:58:19Z","timestamp":1216673899000},"page":"10131-10136","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":156,"title":["Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study"],"prefix":"10.1073","volume":"105","author":[{"given":"A. A.","family":"McCormick","sequence":"first","affiliation":[{"name":"*Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Vacaville, CA 95688;"},{"name":"Touro College of Pharmacy, Touro University, 110 Johnson Lane, Mare Island, Vallejo, CA 94592;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Reddy","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA 94305-5151;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J.","family":"Reinl","sequence":"additional","affiliation":[{"name":"*Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Vacaville, CA 95688;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. I.","family":"Cameron","sequence":"additional","affiliation":[{"name":"*Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Vacaville, CA 95688;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. K.","family":"Czerwinkski","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA 94305-5151;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Vojdani","sequence":"additional","affiliation":[{"name":"*Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Vacaville, CA 95688;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. M.","family":"Hanley","sequence":"additional","affiliation":[{"name":"*Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Vacaville, CA 95688;"},{"name":"CBR International Corporation 2905 Wilderness Place, Suite 202, Boulder, CO 80301;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. J.","family":"Garger","sequence":"additional","affiliation":[{"name":"*Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Vacaville, CA 95688;"},{"name":"Bayer HealthCare, 800 Dwight Way, Berkeley, CA 94701;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. L.","family":"White","sequence":"additional","affiliation":[{"name":"*Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Vacaville, CA 95688;"},{"name":"Integrated Biomolecule Corporation, 2005 Innovation Park Drive, Tucson, AZ 85755;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Novak","sequence":"additional","affiliation":[{"name":"CBR International Corporation 2905 Wilderness Place, Suite 202, Boulder, CO 80301;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Barrett","sequence":"additional","affiliation":[{"name":"**Biologics Consulting Group, Inc., P.O. Box 3025, Evergreen, CO 80437; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. B.","family":"Holtz","sequence":"additional","affiliation":[{"name":"*Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Vacaville, CA 95688;"},{"name":"Holtz Biopharma Consulting, 3930 Accent Drive, #1911, Dallas, TX 75287"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tus\u00e9","sequence":"additional","affiliation":[{"name":"*Large Scale Biology Corporation, 3333 Vaca Valley Parkway, Vacaville, CA 95688;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Levy","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Medicine, Stanford University Medical Center, Stanford, CA 94305-5151;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2008,7,22]]},"reference":[{"key":"e_1_3_3_1_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950101)75:1 <370::AID-CNCR2820751319>3.0.CO;2-Q"},{"key":"e_1_3_3_2_2","first-page":"75","article-title":"Natural history of and therapy for the indolent non-Hodgkin's lymphomas","volume":"20","author":"Horning SJ","year":"1993","unstructured":"SJ Horning, Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20, 75\u201388 (1993).","journal-title":"Semin Oncol"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","article-title":"Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (chop) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with chop alone: Results of a prospective randomized study of the German low-grade lymphoma study group","volume":"106","author":"Hiddemann W","year":"2005","unstructured":"W Hiddemann, et al., Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (chop) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with chop alone: Results of a prospective randomized study of the German low-grade lymphoma study group. Blood 106, 3725\u20133732 (2005).","journal-title":"Blood"},{"key":"e_1_3_3_4_2","first-page":"606","article-title":"Development of targeted therapies for b-cell non-Hodgkin lymphoma and multiple myeloma","volume":"2","author":"Hernandez-Ilizaliturri FJ","year":"2004","unstructured":"FJ Hernandez-Ilizaliturri, A Gowda, MS Czuczman, Development of targeted therapies for b-cell non-Hodgkin lymphoma and multiple myeloma. Clin Adv Hematol Oncol 2, 606\u2013618 (2004).","journal-title":"Clin Adv Hematol Oncol"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3121\/cmr.3.3.157"},{"key":"e_1_3_3_6_2","volume-title":"Non-Hodgkin's Lymphomas","author":"Armitage JO","year":"2001","unstructured":"JO Armitage, NL Harris, P Beirman Non-Hodgkin's Lymphomas (Lippincott-Raven, Philadelphia, 2001)."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.10.3266"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.2.5.485"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3696"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl039"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00564.x"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2000.n.011"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2001.1.221"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.4.6.959"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.164.5.1566"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199210223271705"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/362755a0"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1993.tb44039.x"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.2.580.bloodjournal882580"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.9.3129"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0196-52"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.11.3279.3279"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.2174\/156652305774329221"},{"key":"e_1_3_3_25_2","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.4049\/jimmunol.157.12.5503","article-title":"A nine-amino acid peptide from IL-1\u03b2 augments antitumor immune responses induced by protein and DNA vaccines","volume":"157","author":"Hakim I","year":"1996","unstructured":"I Hakim, S Levy, R Levy, A nine-amino acid peptide from IL-1\u03b2 augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 157, 5503\u20135511 (1996).","journal-title":"J Immunol"},{"key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.159.4.1885","article-title":"DNA vaccines against lymphoma: Promotion of anti-idiotypic antibody responses induced by single chain fv genes by fusion to tetanus toxin fragment c","volume":"159","author":"Spellerberg MB","year":"1997","unstructured":"MB Spellerberg, et al., DNA vaccines against lymphoma: Promotion of anti-idiotypic antibody responses induced by single chain fv genes by fusion to tetanus toxin fragment c. J Immunol 159, 1885\u20131892 (1997).","journal-title":"J Immunol"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.2.703"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(03)00208-4"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj358"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.4289"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.5.2411"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_3_3_33_2","first-page":"314","volume":"51","author":"White E L","year":"2003","unstructured":"E L White, et al. Proc Am Soc Mass Spec Conf Mass Spec Allied Topics 51, 314 (2003).","journal-title":"Proc Am Soc Mass Spec Conf Mass Spec Allied Topics"},{"key":"e_1_3_3_34_2","first-page":"150","volume":"51","author":"Hanley KM","year":"2003","unstructured":"KM Hanley, et al. Proc Am Soc Mass Spec Conf Mass Spec Allied Topics 51, 150 (2003).","journal-title":"Proc Am Soc Mass Spec Conf Mass Spec Allied Topics"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/13928"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1517"},{"key":"e_1_3_3_37_2","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.4049\/jimmunol.162.8.4790","article-title":"DNA vaccination against the idiotype of a murine b cell lymphoma: Mechanism of tumor protection","volume":"162","author":"Syrengelas AD","year":"1999","unstructured":"AD Syrengelas, R Levy, DNA vaccination against the idiotype of a murine b cell lymphoma: Mechanism of tumor protection. J Immunol 162, 4790\u20134795 (1999).","journal-title":"J Immunol"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.5.1370"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2005.11.059"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bth100"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.2438.2438"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.24.18_suppl.7529"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.0803636105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:06:47Z","timestamp":1684469207000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.0803636105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,22]]},"references-count":42,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2008,7,22]]}},"alternative-id":["10.1073\/pnas.0803636105"],"URL":"https:\/\/doi.org\/10.1073\/pnas.0803636105","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,22]]},"assertion":[{"value":"2007-12-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}